“The company developing the drug, #RevolutionMedicines, presented results on May 31, 2026, from its Phase 3 clinical trial of 500 patients with metastatic #PancreaticCancer who had received prior treatment.
Compared to standard #chemotherapy, #daraxonrasib nearly doubled overall survival from 6.7 months to 13.2 months after diagnosis. Overall, daraxonrasib reduced the risk of death for metastatic pancreatic cancer patients by 60%.”

https://www.sciencealert.com/a-breakthrough-drug-just-achieved-the-impossible-for-pancreatic-cancer

Daraxonrasib: Harapan Baru dari Medan Perang Melawan Kanker Pankreas yang Paling Ditakuti

https://legawa.com/2026/06/02/daraxonrasib-harapan-baru-dari-medan-perang-melawan-kanker-pankreas-yang-paling-ditakuti/

Adnkronos - ultimoratop: Cancro al pancreas, pillola sperimentale raddoppia la sopravvivenza: lo studio

(Adnkronos) - L'azienda californiana Revolution Medicines annuncia dati positivi in fase 3: in arrivo la richiesta di via libera alla agenzie regolatorie

Pancreatic cancer, experimental pill doubles survival: the study

(Adnkronos) - The California-based company Revolution Medicines announces positive Phase 3 data: a request for accelerated approval is coming to regulatory agencies.

#California #RevolutionMedicines

https://www.adnkronos.com/cronaca/cancro-pancreas-farmaco-sopravvivenza-tumore_3l8E6ZIMHs7WoZ62LZTk9K